AI measures blood flow to predict death, heart attack—and is more accurate than humans

Researchers have used AI technology to predict a patient’s chance of death, heart attack or stroke better than human doctors, sharing their findings in a new study in Circulation.

The team achieved this breakthrough by, for the first time ever, using AI to instantly measure and evaluate blood flow. In the past, such assessments have been performed using such techniques as cardiovascular magnetic resonance (CMR) imaging. The images, however, were “incredibly difficult” to interpret in a timely manner.

The study’s authors explored data from more than 1,000 patients who underwent routine CMR scans. AI-generated results were then compared with the patients’ outcomes—including death, heart attack, stroke and heart failure—to measure the technique’s effectiveness.

“AI is moving out of the computer labs and into the real world of healthcare, carrying out some tasks better than doctors could do alone,” corresponding author James C. Moon, MD, University College of  London (UCL) Institute of Cardiovascular Science, said in a prepared statement. “We have tried to measure blood flow manually before, but it is tedious and time-consuming, taking doctors away from where they are needed most, with their patients.”

“The predictive power and reliability of the AI was impressive and easy to implement within a patient's routine care,” first author Kristopher D. Knott, MBBS, also of the UCL Institute of Cardiovascular Sciences, said in the same statement. “The calculations were happening as the patients were being scanned, and the results were immediately delivered to doctors. As poor blood flow is treatable, these better predictions ultimately lead to better patient care, as well as giving us new insights into how the heart works.”

Michael Walter
Michael Walter, Managing Editor

Michael has more than 18 years of experience as a professional writer and editor. He has written at length about cardiology, radiology, artificial intelligence and other key healthcare topics.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.